Captor Therapeutics S.A. Announces Molecular Targets of CT-01 Program Developing TPD Therapy for Hepatocellular Carcinoma
another undisclosed neo-substrate with essential function in tumorigenesis. GSPT1 is a protein involved in the termination of translation, a process in which ribosomes synthesize proteins after the transcription of DNA to RNA. There is a demonstrated link between GSPT1 degradation and antitumor activity. SALL4 is a transcription factor expressed in the human fetal liver and silenced in adults but often re-expressed in HCC patients, which correlates with poor prognosis. Captor Therapeutics plans to advance CT-01 towards Investigational New Drug Application (IND)-enabling studies and to initiate clinical trials in 2023.